GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sonnet BioTherapeutics Holdings Inc (NAS:SONN) » Definitions » Cash Flow from Investing

Sonnet BioTherapeutics Holdings (Sonnet BioTherapeutics Holdings) Cash Flow from Investing : $-0.18 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Sonnet BioTherapeutics Holdings Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Sonnet BioTherapeutics Holdings spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Sonnet BioTherapeutics Holdings gained $0.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Sonnet BioTherapeutics Holdings Cash Flow from Investing Historical Data

The historical data trend for Sonnet BioTherapeutics Holdings's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonnet BioTherapeutics Holdings Cash Flow from Investing Chart

Sonnet BioTherapeutics Holdings Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23
Cash Flow from Investing
- -0.08 - -0.81 -0.44

Sonnet BioTherapeutics Holdings Quarterly Data
Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.26 -0.01 -0.17 - -

Sonnet BioTherapeutics Holdings Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Sonnet BioTherapeutics Holdings's Cash Flow from Investing for the fiscal year that ended in Sep. 2023 is calculated as:

Sonnet BioTherapeutics Holdings's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sonnet BioTherapeutics Holdings  (NAS:SONN) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Sonnet BioTherapeutics Holdings's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Sonnet BioTherapeutics Holdings spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Sonnet BioTherapeutics Holdings's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Sonnet BioTherapeutics Holdings gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Sonnet BioTherapeutics Holdings's purchase of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Sonnet BioTherapeutics Holdings spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Sonnet BioTherapeutics Holdings's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Sonnet BioTherapeutics Holdings gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Sonnet BioTherapeutics Holdings's purchase of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means Sonnet BioTherapeutics Holdings spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Sonnet BioTherapeutics Holdings's sale of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means Sonnet BioTherapeutics Holdings gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Sonnet BioTherapeutics Holdings's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.00 Mil. It means Sonnet BioTherapeutics Holdings paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Sonnet BioTherapeutics Holdings's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means Sonnet BioTherapeutics Holdings paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Sonnet BioTherapeutics Holdings's cash from other investing activities for the three months ended in Mar. 2024 was $0.00 Mil. It means Sonnet BioTherapeutics Holdings paid $0.00 Mil for other investing activities.


Sonnet BioTherapeutics Holdings Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Sonnet BioTherapeutics Holdings's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Sonnet BioTherapeutics Holdings (Sonnet BioTherapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
100 Overlook Center, Suite 102, Princeton, NJ, USA, 08540
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
Executives
John Markey 10 percent owner 10096 RIDGEWOOD DRIVE, TWINSBURG OH 44087
Susan Dexter officer: Chief Technical Officer C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Albert D. Dyrness director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Nailesh Bhatt director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Pankaj Mohan director, officer: Chairman, President and CEO C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Lori Mcneill director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, SUITE 102, PRINCETON NJ 08540
Richard T Kenney officer: Chief Medical Officer C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Donald J. Griffith director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Terence Anthony Rugg officer: Chief Medical Officer C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
John K. Cini officer: Chief Scientific Officer C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Raghu Rao director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Cross John Harry Iii officer: Chief Financial Officer C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Oz Rey Llc 10 percent owner 918 CONGRESS AVENUE, SUITE 100, AUSTIN TX 78701
Mv Amanth Llc 10 percent owner 515 CONGRESS AVE, STE 1400, AUSTIN TX 78701-3516
Robert Sumner Hersch 10 percent owner 515 CONGRESS AVE, STE 1400, AUSTIN TX 78701